BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Business

  CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

  CASI Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2022, and provided an update on key highlights for 2022.

  April 26, 2023

   · 

  14 min read
• Business

  GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023

  GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET.

  April 26, 2023

   · 

  1 min read
• Drug Development

  AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023

  AlloVir, Inc. today announced the presentation of positive long-term, follow-up data from the Phase 2 study of posoleucel for the prevention of clinically significant infections from six common and devastating viruses in allogeneic hematopoietic cell transplant (allo-HCT) recipients.

  April 26, 2023

   · 

  8 min read
• Pharm Country

  MindMed to Participate in May Investor Conferences

  Mind Medicine announced today that members of the Company’s management team will participate in the following investor conferences.

  April 26, 2023

   · 

  1 min read
• Business

  Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

  Surmodics, Inc. today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023.

  April 26, 2023

   · 

  22 min read
• Drug Development

  Uvax Bio Announces Publication of Results from Preclinical Studies of HIV Vaccine Candidates

  Uvax Bio , LLC today announced that its HIV vaccine candidates have shown significant improvement in immune response compared with current vaccine strategies.

  April 26, 2023

   · 

  3 min read
• Biotech Bay

  Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases

  Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the completion of a $50 million Series B financing.

  April 26, 2023

   · 

  2 min read
• Business

  X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2023 on Thursday, May 4, 2023.

  April 26, 2023

   · 

  2 min read
• Business

  Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023

  Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced it will report its first quarter 2023 financial results and provide an update on the cytisinicline development program on Tuesday, May 9, 2023 at 4:30 PM EDT.

  April 26, 2023

   · 

  4 min read
• Drug Development

  Direct Biologics Receives FDA Clearance to Initiate Phase 1b/2a Clinical Trial of ExoFlo™ in Patients with Medically Refractory Perianal Fistulizing Crohn’s Disease

  Direct Biologics, LLC announces U.S. Food and Drug Administration (FDA) clearance of the Company’s investigational new drug (IND) application for a Phase 1b/2a clinical trial to evaluate the safety and efficacy of ExoFlo™ for the treatment of medically refractory perianal fistulizing Crohn’s disease (CD).

  April 26, 2023

   · 

  4 min read